Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adipose stem cell therapy - Anterogen

Next Previous
Drug Profile

Adipose stem cell therapy - Anterogen

Alternative Names: Allogeneic mesenchymal stem cells - Anterogen; Adipocell (Anterogen); AdipoPlus; Adipose-derived stem cells; ALLO-ASC; ALLO-ASC-DFU; ALLO-ASC-EB; ALLO-ASC-OA; ALLO-ASC-SHEET; ALLO-ASC-TI; Allogeneic adipose stem cells; ANTG-ASC; Autologous adipose stem cells; Cupistem; Queencell

Latest Information Update: 24 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Anterogen
  • Class Mesenchymal stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rectal fistula
  • New Molecular Entity No

Highest Development Phases

  • Marketed Rectal fistula; Scars; Subcutaneous fat disorders
  • Phase III Crohn's disease; Diabetic foot ulcer
  • Phase II Epidermolysis bullosa
  • Phase I/II Tendon injuries
  • Phase I Osteoarthritis
  • No development reported Burns; Chronic wounds; IgA nephropathy

Most Recent Events

  • 22 Oct 2024 Phase-I clinical trials in Osteoarthritis in South Korea (Parenteral) (NCT06539429)
  • 06 Aug 2024 Anterogen plans a phase I trial for osteoarthritis (In adults, In the elderly) in South Korea (Parenteral), in August 2024 (NCT06539429)
  • 23 Oct 2023 Anterogen completes a phase-II trial in Diabetic foot ulcer in USA (Parenteral) (NCT03754465)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top